Advanced Filters
noise

Anemia; Non-Small-Cell Lung Cancer Clinical Trials

A listing of Anemia; Non-Small-Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 402 clinical trials

The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.

Migraine is a frequent and debilitating neurologic disorder. It is more frequent in women, and more prevalent in patients with autoimmune and/or inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn's disease (CD), systemic lupus erythematosus (SLE) and endometriosis, whereas patients with long standing type 1 diabetes mellitus …

18 - 50 years of age Female Phase N/A
J José Pereira, MD

Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing with Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment

This trial is part of the spastiCRYO clinical research project. The primary objective of this clinical trial is to test the hypothesis: "Upper limb nerve cryoneurolysis is non inferior to the usual care and has therapeutic add value in dealing with shoulder pain and functional problems caused by spasticity and …

18 years of age All Phase N/A

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Multiple sclerosis (MS) affects approximately 2.3 million patients worldwide, with a global median prevalence of 33 per 100,000. MS is diagnosed at an average of 30 years and affects twice as many women as men. MS is traditionally diagnosed by the presentation of lesions of the central nervous system, disseminated …

18 years of age All Phase N/A
M Maria Leandro

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of patients (single-arm). The …

18 - 60 years of age All Phase 1

Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

Phase I / II randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin administration combined with ocrelizumab in patients with Progressive Multiple Primary Sclerosis.

18 - 65 years of age All Phase 1/2
M Mads Hvid Aaberg Poulsen

Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction

A multi-center double-blinded placebo-controlled randomized clinical trial. The patients will be randomized into two groups. To investigate the efficacy of SNM to improve the key bladder diary variables compared to placebo (i.e. sham) for patients with MS having refractory neurogenic lower urinary tract dysfunction (NLUTD). After first step SNM-procedure and …

18 - 80 years of age All Phase N/A
N Nicola Smania, MD

Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation

The first aim of this project is to investigate the effects of different high-tech neurorehabilitation interventions (cognitive, motor, and combined cognitive-motor) on both cognitive and motor disability outcomes in people with multiple sclerosis (MS). The second aim is to identify the cognitive and motor profiles of MS patients who benefit …

18 years of age All Phase N/A

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

Rationale: Ocrelizumab is widely and effectively used to treat relapsing multiple sclerosis (RMS). Phase II studies and data from large patient cohorts indicate that rituximab, another anti-CD20 monoclonal antibody, is probably equally effective and safe as ocrelizumab in the treatment of RMS. An advantage of rituximab is a considerably lower …

18 years of age All Phase 3
L Lucia Bianchi, PhD

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.

18 - 65 years of age All Phase 1

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

The aim of this project is to assess properly the clinical efficacy of TolDec therapy by imaging, clinical and surrogate end-points related with the activity of the disease.

18 years of age All Phase 2

Simplify language using AI